BioAge Labs, Inc. (BIOA) earnings
BIOA earnings moved a median of +0.56% by the close. Quarterly and annual BIOA reports and results, each read against the price at its own news timestamp. Back to the BIOA overview →
21 measured BIOA earnings events.
Where these BIOA earnings landedvs 21 measured BIOA earnings reactions
| Middle 50% of BIOA earnings reactions | -0.90% to +2.68% |
|---|---|
| Median reaction (to close) | +0.56% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 BIOA earnings events with a measured close landed between -0.90% and +2.68%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST | Press release | -1.87% | +0.56% | |
| BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | -0.05% | +3.30% | |
| Form 10-Q BioAge Labs, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.05% | +3.30% | |
| Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET | Press release | -0.54% | +3.18% | |
| BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | -0.23% | +2.68% | |
| Form 10-Q BioAge Labs, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.23% | +2.68% | |
| BioArctic publishes the Annual Report and Sustainability Report for 2025 | Press release | +0.66% | -0.63% | |
| Form 10-K BioAge Labs, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.49% | -12.87% | |
| Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET | Press release | -0.62% | -0.99% | |
| Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 | Press release | +4.40% | +2.52% | |
| BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | +1.51% | -0.14% | |
| Form 10-Q BioAge Labs, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.51% | -0.14% | |
| Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET | Press release | -1.18% | +1.22% | |
| Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET | Press release | -0.89% | +0.00% | |
| BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates | Press release | +0.00% | -2.04% | |
| Form 10-Q BioAge Labs, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -2.04% | |
| Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 | Press release | +0.00% | -0.90% | |
| Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET | Press release | -1.58% | -2.68% | |
| BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates | Press release | +0.50% | +2.01% | |
| Form 10-Q BioAge Labs, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.50% | +2.01% | |
| Form 10-K BioAge Labs, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +5.90% |
Keep exploring
More BIOA: analyst actions → · SEC filings → · BIOA overview →